ClinicalTrials.gg

Program

ZE66-0205

A development code.

Its studies are led by Eilean Therapeutics.

Furthest: phase 1, since Jul 24, 20261 company-led study, 1 open or runningNext primary completion: Aug 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eilean Therapeutics11 open or runningphase 1since Jul 24, 2026Jul 24, 2026Aug 15, 2027phase 1 · NCT07735728

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 24, 2026First study: phase 1 study in Healthy Volunteers (HV)First studyNCT07735728 · 32 planned · Australia

Ahead

  1. Aug 15, 2027Primary completion: phase 1 study in Healthy Volunteers (HV)NCT07735728

TargetBeta

MALT1 →read by rule
“The study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ZE66-0205, a novel orally administered small-molecule degrader of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1).”study text, by rule · the study

Other programs on MALT1

ProgramCompanyFurthest phaseStudies
safimaltibruleJohnson & Johnsonphase 14
CARD11-BCL10-MALT1 Complex Inhibitor XL114ruleDr. Reddy's Laboratoriesphase 12

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07735728Healthy Volunteers (HV) · Australia1RecruitingAug 15, 202732

How it is read

Names in the registry

  • “ZE66-0205”, 1 entry

Codes read as this program: ZE660205.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.